Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06XGW
|
|||
| Former ID |
DIB009066
|
|||
| Drug Name |
Acetylcysteine
|
|||
| Synonyms |
Acetadone EF; Acetadote ALF; Acetylcysteine, Cumberland Pharmaceuticals
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Liver disease [ICD-11: DB90-BD99] | Approved | [1] | |
| Company |
Cumberland Pharmaceuticals Inc; RxKinetix
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H9NO3S
|
|||
| Canonical SMILES |
CC(=O)NC(CS)C(=O)O
|
|||
| InChI |
1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1
|
|||
| InChIKey |
PWKSKIMOESPYIA-BYPYZUCNSA-N
|
|||
| CAS Number |
CAS 616-91-1
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:28939
|
|||
| ADReCS Drug ID | BADD_D00032 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Bifidobacterium was increased by Acetylcysteine (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Desulfovibrionales | ||||
|
Studied Microbe: Desulfovibrio
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Desulfovibrio was decreased by Acetylcysteine (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Allobaculum
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Allobaculum was increased by Acetylcysteine (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Blautia was decreased by Acetylcysteine (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Lactobacillus was increased by Acetylcysteine (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Akkermansia was increased by Acetylcysteine (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Bacteroidetes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Bacteroidetes was decreased by Acetylcysteine (p < 0.05). | |||
|
Studied Microbe: Firmicutes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Firmicutes was decreased by Acetylcysteine (p < 0.05). | |||
|
Studied Microbe: Proteobacteria
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Proteobacteria was decreased by Acetylcysteine (p < 0.05). | |||
|
Studied Microbe: Verrucomicrobia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6J mice | Experimental Sample | Faeces | |
| Disease or Condition | Intestinal dysbiosis and glucose metabolic disorder | |||
| Description | The abundance of Verrucomicrobia was decreased by Acetylcysteine (p < 0.05). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | N-Acetylcysteine alleviates gut dysbiosis and glucose metabolic disorder in high-fat diet-fed mice. J Diabetes. 2019 Jan;11(1):32-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.